Rhamnazin
Based on 1 publication(s) in Google Scholar
Rhamnazin is an orally active inhibitor of VEGFR2 signaling with an IC50 of 4.68 μM against VEGFR2 kinase. Rhamnazin shows potent antiangiogenic activity and antitumor efficacy. Rhamnazin shows antioxidant and anti-inflammatory properties.
For research use only. We do not sell to patients.
- Purity : 99.00%
- CAS No.: 552-54-5
- Formula: C17H14O7
- Molecular Weight:330.29
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) Rhamnazin
MoreAll VEGFR Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
VEGFR2 4.68 μM (IC50) |
In Vitro
Rhamnazin (5-40 μM) inhibits proliferation, migration and tube formation of HUVECs induced by VEGF[1].
Rhamnazin (0-20 μM) attenuates VEGFR-2 tyrosine kinase activity and VEGFR-2 signaling pathway[1].
Rhamnazin (0-40 μM; 24 h) inhibits the proliferation and VEGFR2 signaling pathway of breast cancer cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HUVECs
-
Concentration:0, 10, 15 and 20 μM
-
Incubation Time:6 h
-
Result:Strongly inhibited the migration of HUVECs.
-
Cell Line:HUVECs
-
Concentration:0, 10, 15 and 20 μM
-
Incubation Time:24 h
-
Result:Decreased VEGF binding to VEGFR2. Reduced VEGF-stimulated phosphorylation of VEGFR2 and its downstream MAPK, AKT, and STAT3 in HUVECs in a concentrationdependent manner.
-
Cell Line:HCC1937, T-47D, SK-BR-3, MCF-7 and MDA-MB-231
-
Concentration:0, 10, 15, 20, 30 and 40 μM
-
Incubation Time:24 h
-
Result:Inhibited cell growth with IC50s of 19, 27, 32, 41 and 64 μM against MDA-MB-231, MCF-7, SK-BR-3, T-47D and HCC1937 in the presence of VEGF, respectively.
In Vivo
Rhamnazin (5-20 mg/kg; i.p.; once) shows strong antioxidant and anti-inflammatory properties in the rat acute lung injury model[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude mice, breast cancer xenograft model[1]
-
Dosage:200 mg/kg
-
Administration:Intragastric administration, daily for 25 days
-
Result:Dramatically suppressed tumor volumes by 47% compared with the vehicle group. Showed a significant reduction of pVEGFR2Tyr951-positive cells in tumors. Resulted in downregulation of VEGFR2 downstream molecules phosphorylation including MAPK, AKT and STAT3.
Chemical Information
-
CAS No. 552-54-5
-
Appearance Solid
-
Molecular Weight 330.29
-
Formula C17H14O7
-
Color Off-white to light yellow
-
SMILES
O=C1C(O)=C(C2=CC=C(O)C(OC)=C2)OC3=CC(OC)=CC(O)=C13
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Sci Rep
Investigation of Scutellaria Barbata's immunological mechanism against thyroid cancer using network pharmacology and experimental validation. [Abstract]2025 Jan 20;15(1):2490. PMID: 39833432
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (302.76 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Yu Y, et al. Rhamnazin, a novel inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy. Biochem Biophys Res Commun. 2015 Mar 20;458(4):913-9. [Content Brief]
[2]. Wu G, et al. ANTIOXIDANT AND ANTI-INFLAMMATORY EFFECTS OF RHAMNAZIN ON LIPOPOLYSACCHARIDE-INDUCED ACUTE LUNG INJURY AND INFLAMMATION IN RATS. Afr J Tradit Complement Altern Med. 2017 Jun 5;14(4):201-212. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.0276 mL | 15.1382 mL | 30.2764 mL | 75.6911 mL |
| 5 mM | 0.6055 mL | 3.0276 mL | 6.0553 mL | 15.1382 mL | |
| 10 mM | 0.3028 mL | 1.5138 mL | 3.0276 mL | 7.5691 mL | |
| 15 mM | 0.2018 mL | 1.0092 mL | 2.0184 mL | 5.0461 mL | |
| 20 mM | 0.1514 mL | 0.7569 mL | 1.5138 mL | 3.7846 mL | |
| 25 mM | 0.1211 mL | 0.6055 mL | 1.2111 mL | 3.0276 mL | |
| 30 mM | 0.1009 mL | 0.5046 mL | 1.0092 mL | 2.5230 mL | |
| 40 mM | 0.0757 mL | 0.3785 mL | 0.7569 mL | 1.8923 mL | |
| 50 mM | 0.0606 mL | 0.3028 mL | 0.6055 mL | 1.5138 mL | |
| 60 mM | 0.0505 mL | 0.2523 mL | 0.5046 mL | 1.2615 mL | |
| 80 mM | 0.0378 mL | 0.1892 mL | 0.3785 mL | 0.9461 mL | |
| 100 mM | 0.0303 mL | 0.1514 mL | 0.3028 mL | 0.7569 mL |